DNA minor-groove binders: Results and design of new antitumor agents

Farmaco

Volumn 54, Issue 1-2, 1999, Pages 15-25

  Baraldi, Pier Giovanni ^a   Cacciari, Barbara ^a   Guiotto, Andrea ^a   Romagnoli, Romeo ^a   Zaid, Abdel Naser ^a   Spalluto, Giampiero ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Antitumor agents; CC 1065; Distamycin; PBD

Indexed keywords

ADOZELESIN; ALKYLATING AGENT; ANTHRAMYCIN; ANTINEOPLASTIC AGENT; BIZELESIN; CARZELESIN; DISTAMYCIN A; DNA; PIBROZELESIN; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; RACHELMYCIN; TALLIMUSTINE; U 71184; UNCLASSIFIED DRUG;

BINDING SITE; CANCER; DRUG DESIGN; DRUG DNA BINDING; DRUG STRUCTURE; DRUG USE; GENE EXPRESSION REGULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; DNA, NEOPLASM; HUMANS;

EID: 0032945663     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(98)00102-5     Document Type: Review

References (71)

1. Leimgruber W., Stefanovich V., Schenker F., Karr A., Berger J. Isolation and characterization of anthramycin a new antitumor antibiotic. J. Am. Chem. Soc. 87:1965;5791-5793.
2. Leimgruber W., Batcho A.D., Schenker F. The structure of anthramycin. J. Am. Chem. Soc. 87:1965;5793-5975.
3. Arora S.K. Structural investigation of the mode of action of drugs. II. Molecular structure of anthramycin methyl ether monohydrate. Acta Crystallogr., Sect. B. 35:1979;2945-2948.
4. Tendler M.D., Corman S. Refuin: a non cytotoxic carcinostatic compound proliferated by a thermophilic actinomicete. Nature. 199:1963;501.
5. Kohn K.W., Spears C.L. Reaction of anthramycin with deoxyribonucleic acid. J. Mol. Biol. 51:1970;551-572.
6. Glaubiger D., Kohn K.W., Charney E. The reaction of anthramycin with DNA. III. Properties of the complex. Biochim. Biophys. Acta. 361:1974;303-311.
7. Kohn K.W., Glaubiger D., Spears C.L. The reaction of anthramycin with DNA. II. Studies of kinetics and mechanism. Biochim. Biophys. Acta. 361:1974;288-302.
8. Graves D.E., Pattaroni C., Krishnan B., Ostrander J.M., Hurley L.H., Krugh R.T. The reaction of anthramycin with DNA. Proton and carbon nuclear magnetic resonance studies on the structure of the anthramycin-DNA adduct. J. Biol. Chem. 259:1984;8202-8209.
9. Hurley L.H., Reck T., Thurston D.E., Langley D.R., Holden K.G., Hertzberg R.P., Hoover J.R.E., Gallagher G. Jr., Faucette L.F., Mong S.M., Johnson R.K. Pyrrolo[1,4]benzodiazepines antitumor antibiotics. Relationship of DNA binding and sequence specificity to biological activities of natural and synthetic compound. Chem. Res. Toxicol. 1:1988;258-268.
10. Thurston D.E. Advances in the study of pyrrolo[2,1-c][1,4]-benzodiazepine (PBD) antitumour antibiotics. Neidle S., Waring M.J. Molecular Aspects of Anticancer Drug-DNA Interactions. 1:1993;54-88 MacMillan, London.
11. Thurston D.E., Hurley L.H. A rational basis for development of antitumor agents in the pyrrolo[1,4]benzodiazepine group. Drugs Future. 8:1984;957-971.
12. Hurley L.H. Pyrrolo[1,4]benzodiazepine antitumor antibiotics. Comparative aspects of anthramycin, tomaymycin, and sibiromycin. J. Antibiot. 30:1977;349-370.
13. 13C-NMR spectroscopy. J. Supramol. Struct. Cell. Biochem. Suppl. 5:1981;168.
14. Kopka M.L., Goodsell D.S., Baikalov I., Grzeskowiak K., Cascio D., Dickerson R.E. Crystal structure of a covalent DNA-drug adduct: anthramycin bound to C-C-A-A-C-G-T-T-G-G, and a molecular explanation of specificity. Biochemistry. 33:1994;13593-13610.
15. Aoki H., Miyairi M., Ajisaka M., Sakai H. Dextrochrysin, a new antibiotic. J. Antibiot. 22:1969;201-206.
16. Shorin V.A., Rossolima O.K. Experimental studies on antitumor activity of sibiromycin. Antibiotiki. 5:1970;300-304.
17. Horwitz S.B., Chang S.C., Grollman A.P., Borkovec A.B. Chemosterillant action of anthramycin: a proposed mechanism. Science. 147:1971;159-161.
18. Gause G.F., Dudnik Y.V. Interaction of antitumor antibiotics with DNA: studies on sibiromycin. Progr. Mol. Subcell. Biol. 2:1971;33-39.
19. Adamson R.H., Hart L.G., DeVita V.T., Oliverio V.T. Antitumor activity and some pharmacological properties of anthramycin methyl ether. Cancer Res. 28:1968;343-347.
20. G. Zbinden, in: A. Plattner (Ed.), Chemotherapy of Cancer, Proceedings of International Symposium Lugano, Elsevier, New York, 1964, pp. 303-310.
21. Cargill C., Bachmann E., Zbinden G. Effect of daunomycin and anthramycin on electrocardiogrm and mithocondrial metabolism of the rat heart. J. Natl. Cancer Inst. 53:1974;481-486.
22. Bazhanov V.S., Shepelevteva N.G. Comparative studies on antitumor activity and toxicity of sibiromycin and its sulfur-containing derivatives. Antibiotiki. 18:1973;714-717.
23. Korman S., Tendler M.D. Clinical investigation of cancer chemotherapeutic agents for neoplastic disease. J. New Drugs. 5:1965;275-285.
24. P.G. Baraldi, A. Leoni, Analoghi eterociclici di pirrolo[1,4]benzodiazepine ad attività antitumorale, Italian patent Appl. MI92 A 001913, 1992.
25. Baraldi P.G., Leoni A., Cacciari B., Manfredini S., Simoni D. Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogs of pyrrolo[1,4]benzodiazepines (PBDs). Bioorg. Med. Chem. Lett. 3:1993;2511-2514.
26. (a) D.R. Langley, D.E. Thurston, A versatile and efficient synthesis of carbinolamine containing pyrrolo[1,4]benzodiazepines via the cyclization of N-(2 aminobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetals: total synthesis of prothracarcin, J. Org. Chem. 52 (1987) 91-97.
27. (b) D.E. Thurston, D.S. Bose, Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines, Chem. Rev. 94 (1994) 433-465.
28. (c) P.G. Baraldi, A. Leoni, B. Cacciari, S. Manfredini, D. Simoni, M. Bergomi, E. Menta, S. Spinelli, Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogues of pyrrolo[1,4][2,1-c]benzodiazepines, J. Med. Chem. 37 (1994) 4329-4337.
29. Baraldi P.G., Beria I., Cacciari B., Leoni A., Spalluto G. Synthesis and cytotoxicity of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepinone heterocyclic analogs. Minerva Biotecn. 7:1995;188-199.
30. P.G. Baraldi, unpublished results.
31. Hanka L.J., Dietz A., Gerpheide S.A., Kuentzel S.L., Martin D.G. CC-1065 (NSC 298223) a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J. Antibiot. 31:1995;1211-1217.
32. Martin D.G., Chidester C.G., Duchamp D.J., Mizsak S.A. Structure of CC-1065 (NSC 298223), a new antitumor antibiotic. J. Antibiot. 33:1980;902-903.
33. Takahashi I., Takahashi K., Ichimura M., Morimoto M., Asano K., Kawamoto I., Tomita F., Nakano H. Duocarmycin A, a new antibiotic from Streptomyces. J. Antibiot. 41:1988;1915-1917.
34. Yasuzawa T., Iida T., Muroi K., Ichimura M., Takahashi K., Sano H. Structure of duocarmycins produced by Streptomyces sp. Chem. Pharm. Bull. 36:1988;3728-3731.
35. Boger D.L., Johnson D.S. CC-1065 and the duocarmycins: unravelling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl. Acad. Sci. USA. 92:1995;3642-3649.
36. Boger D.L. The duocarmycins: synthetic and mechanicistic studies. Acc. Chem. Res. 28:1995;20-29.
37. (a) W. Wrasidlo, D.S. Johnson, D.L. Boger, Induction of endonucleolytic DNA fragmentation and apoptosis by the duocarmycins, Bioorg. Med. Chem. Lett. 4 (1994) 631-636.
38. (b) D.L. Boger, D.S. Johnson, W. Yun, (+)- and ent-(-)-duocarmycin SA and (+)- and ent-(-)-N-Boc-DSA DNA alkylation properties. Alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity of enantiomeric agents, J. Am. Chem. Soc. 116 (1994) 1635-1656.
39. (a) L.H. Hurley, V.L. Reynolds, G.L. Swenson, G.L. Petzold, T.A. Scahill, Reaction of the antitumor antibiotic CC-1065 with DNA: structure of DNA adduct with DNA sequence specificity, Science 226 (1984) 843-844.
40. (b) V.L. Reynolds, I.J. Molineaux, D.G. Kaplan, D.H. Swenson, L.H. Hurley, Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally-induced strand breakage and analysis of DNA sequence specificity, Biochemistry 24 (1985) 6228-6237.
41. Aristoff P.A. CC-1065 Analogs: sequence specific DNA-alkylating antitumor agents. Adv. Med. Chem. 2:1993;67-110.
42. McGovern J.P., Clarke G.L., Pratt E.A., DeKoning T.F. Preliminary toxicity studies with DNA-binding antibiotic, CC-1065. J. Antibiot. 37:1984;63-70.
43. Wierenga W. Sequence-selective DNA-interactive antitumor agents. Drugs Future. 16:1991;741-750.
44. Hightower R.D., Sevin B.-U., Perras J., Nguyen H., Angioli R., Untch M., Averette H. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779 and U-80,244 in gynecologic cancer cell lines. Cancer Invest. 11:1993;276-282.
45. Li L.H., Kelly R.C., Warpehoski M.A., McGovern J.P., Gebhard I., Dekoning T.F. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA binding antibiotic, CC-1065. Inv. New Drugs. 9:1991;137-148.
46. Li L.H., DeKoning T.F., Kelly R.C., Krueger W.C., McGovern J.P., Padbury G.E., Petzold G.L., Wallace T.L., Ouding R.J., Prairie M.D., Gebhard I. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopyrroloindole analog. Cancer Res. 52:1992;4909-4913.
47. Walker D.L., Reid J.M., Ames M.M. Preclinical pharmacology of bizelesin, a potent bifunctional analog of DNA-binding antibiotic CC-1065. Cancer Chemother. Pharmacol. 34:1994;317-322.
48. Kobayashi E., Okamoto A., Asada M., Okabe M., Nagamura S., Asai A., Saito A., Gomi K., Hirata T. Characteristics of antitumor activity of KW-2189, a novel water soluble derivative of duocarmycin against murine and human tumors. Cancer Res. 54:1994;2404-2410.
49. Boger D.L., Johnson D.S. CC-1065 and the Duocarmycins: Understanding their biological function through mechanistic studies. Angew. Chem., Int. Ed. Engl. 35:1996;1438-1474.
50. P. Cozzi, I. Beria, L. Capolongo, P.G.G. Baraldi, Spalluto, Indazole [3,2-e]-pyrrole and 1,2,3-benzotriazole [3,2-e]-pyrrole derivatives, UK Patent, Appl. GB 2300857 A, 1996.
51. Baraldi P.G., Cacciari B., Pineda de Las Infantas M.J., Romagnoli R., Spalluto G., Cozzi P., Mongelli N. Synthesis, chemical solvolytic stability and preliminary biological evaluation of (+)-N-Boc-CPzI: a pyrazole analog of the left-hand segment of the antitumor agent CC-1065. Anti Cancer Drug Des. 12:1997;67-74.
52. Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., Gambari R., Bianchi N., Passadore M., Ambrosino P., Mongelli N., Cozzi P., Geroni C. Synthesis, cytotoxicity, antitumor activity and sequence selective binding of two pyrazole analogs structurally related to the antitumor agents U-71,184 and adozelesin. Anti Cancer Drug Des. 12:1997;555-576.
53. Baraldi P.G., Cacciari B., Guiotto A., Romagnoli R., Spalluto G., Zaid A.N., Cozzi P., Ceroni C., Capolongo L., Mongelli N. Synthesis, solvolytic stability and cytotoxicity of a modified derivative of CPzI, a pyrazole analog of the alkylation subunit of the antitumor agent CC-1065: effect of the nitrogen substitution on the functional reactivity. Farmaco. 52:1997;717-723.
54. Nagamura S., Kobayashi E., Gomi K., Saito H. Studies on the active metabolise (DU-86) of KW-2189, a novel derivative of duocarmycin. Bioorg. Med. Chem. Lett. 6:1996;2147-2150.
55. Baraldi P.G., Cacciari B., Guiotto A., Romagnoli R., Spalluto G., Zaid A.N., Cozzi P., Geroni C., Mongelli N. Synthesis, cytotoxicity and antitumor activity of some new simplified pyrazole analogs of the antitumor agent CC-1065. Effect of an hydrophobic group on antitumor activity. Farmaco. 52:1997;711-716.
56. Di Marco A., Gaetani M., Orezzi P., Scotti T., Arcamone F. Isolation and antitumor activity of an antibiotic from streptomices. Giorn. Microbiol. 9:1961;83-90.
57. Casazza A.M., Fioretti A., Ghione M., Soldati M., Verini M.A. Distamycin A: an antiviral antibiotic. Antimicrob. Agents Chemoter. 5:1965;593-598.
58. Pelton J.G., Wemmer D.E. Binding modes of distamycin A with d(CGCAAATTTGCG)2 determined by two-dimensional NMR. J. Am. Chem. Soc. 112:1990;1393-1399.
59. Lown J.W., Krowichi K., Bhat U.G., Skorobogaty A., Ward B., Dabrowiak J.C. Molecular recognition between oligopeptides and nucleic acids. Novel imidazole containing oligopeptides related to netropsin that exhibit altered DNA sequence specificity. Biochemistry. 25:1986;7408-7416.
60. D'Alessio R., Geroni C., Biasoli G., Pesenti E., Grandi M., Mongelli N. Structure activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorg. Med. Chem. Lett. 4:1994;1467-1472.
61. Schultz P.G., Dervan P.B. Sequence-specific double-strand cleavage of DNA by penta-N-methylpyrrolecarboxamido-EDTA-Fe(II). Proc. Natl. Acad. Sci. USA. 80:1983;6834-6837.
62. J.A. Hartley, S. Neidle, M.J. Waring (Eds.), Molecular Aspects of Anticancer Drug-DNA Interactions, Macmillan, London.
63. Arcamone F., Penco S., Orezzi P., Nicolella V., Pirelli A. Structure and synthesis of distamycin A. Nature. 203:1964;1064-1065.
64. Boggini M., D'Incalci M. Modulation of transcription factor-DNA interactions by anticancer drugs. Anti Cancer Drug Des. 9:1994;373-387.
65. Arcamone F., Nicolella V., Penco S., Redaelli S. Distamycin A: synthesis of analogs with different numbers of 1-methyl-4-aminopyrrole-2-carboxylic residues. Gazz. Chim. Ital. 99:1969;632-640.
66. Arcamone F.M., Animati F., Barbieri B., Configliacchi E., D'Alessio R., Geroni C., Giuliani F.C., Lazzari E., Menozzi M., Mongelli N., Penco S., Verini M.A. Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. J. Med. Chem. 32:1989;774-778.
67. Cozzi P., Beria I., Biasoli G., Caldarelli M., Capolongo L., Geroni C., Mongelli N. Novel phenyl nitrogen mustard and half-mustard derivatives of amidino modified distamycin. Bioorg. Med. Chem. Lett. 7:1997;2979-2984.
68. Baraldi P.G., Beria I., Cacciari B., Cozzi P., Franzetti C., Mongelli N., Romagnoli R., Spalluto G. Synthesis and antitumor activity of novel distamycin derivatives. Bioorg. Med. Chem. Lett. 6:1996;1241-1246.
69. Baraldi P.G., Beria I., Cacciari B., Capolongo L., Cozzi P., Mongelli N., Romagnoli R., Spalluto G. Structure-activity relationship of novel tallimustine derivatives: synthesis and antitumor activity. Bioorg. Med. Chem. Lett. 6:1996;1247-1252.
70. Bailly C., Henichart J.P. DNA recognition by intercalator-minor-groove binder hybrid molecules. Bioconj. Chem. 2:1991;379-393.
71. Baraldi P.G., Cacciari B., Guiotto A., Leoni A., Romagnoli R., Spalluto G., Mongelli N., Thurston D.E., Bianchi N., Gambari R. Design, synthesis and biological activity of pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid. Bioorg. Med. Chem. Lett. 8:1998;3019-3024.